{
    "clinical_study": {
        "@rank": "75646", 
        "arm_group": [
            {
                "arm_group_label": "Jinlida granules", 
                "arm_group_type": "Experimental", 
                "description": "Jinlida granules, a traditional Chinese medicine, was a herbal formula which was developed under cognition of the theory in the onset of diabetes"
            }, 
            {
                "arm_group_label": "placebo granules", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo prepared in indistinguishable granules"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the present study is to evaluate the efficacy and safety of Jinlida granules in\n      patients with inadequately controlled type-2 diabetes and dyslipidemia under life style\n      intervention."
        }, 
        "brief_title": "Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study)", 
        "condition": [
            "Type 2 Diabetes", 
            "Dyslipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Dyslipidemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age of 20-70 years;\n\n          2. diagnosed with type 2 diabetes inadequately controlled under life style intervention\n             with 3 months before screening;\n\n          3. HbA1c \u22656.5% and \u226410.0%, and fasting plasma glucose \u22657 and \u226413.3mmol/L at baseline;\n\n          4. diagnosed with dislipidemia with triglycerides>150mg/dL (1.70mmol/L), and/or total\n             cholesterol >200mg/dL (5.16mmol/L), and/or LDL-c>100mg/dL (2.58mmol/L)\n\n          5. body mass index (BMI): 20<BMI<40 kg/m2;\n\n        Exclusion Criteria:\n\n          1. moderate or severe liver dysfunction, abnormal renal function;\n\n          2. severe dysfunction of the heart;\n\n          3. histories of acute diabetic complications including diabetic ketoacidosis or\n             hyperosmolar hyperglycemic non-ketotic coma within 3 months;\n\n          4. psychiatric disease or severe infection;\n\n          5. pregnancy or planned pregnancy;\n\n          6. use of any drug (including insulin) for treatment of diabetes or dyslipidemia within\n             3 months;\n\n          7. use of chronic (>7 days) systemic glucocorticoid therapy within 8 weeks or receive\n             growth hormone therapy within 6 months;\n\n          8. diagnosed with type 1 diabetes, or gestational diabetes, or other specific types of\n             diabetes;\n\n          9. history of malignant tumor within 5 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035644", 
            "org_study_id": "CCEMD021"
        }, 
        "intervention": [
            {
                "arm_group_label": "Jinlida granules", 
                "intervention_name": "Jinlida granules", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo granules", 
                "intervention_name": "placebo granules", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "Guang Ning"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "last_name": "Guang Ning, MD, PHD", 
            "phone": "8621-64370045", 
            "phone_ext": "665344"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change in HbA1c levels", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035644"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Guang Ning", 
            "investigator_title": "the vice-president of Shanghai Jiao Tong University Affiliated Ruijin Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "fasting, postload 30-min and 2-h plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "fasting, postload 30-min and 2-h serum insulin", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "serum lipids", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "glucose disposal rate (GDR) values from hyperinsulinemic euglycemic clamp", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "incretins", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "metabolomic parameters", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "BMI", 
                "safety_issue": "Yes", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "blood pressures", 
                "safety_issue": "Yes", 
                "time_frame": "16 weeks"
            }
        ], 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "Shijiazhuang Yiling Pharmaceutical company, LTD", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}